XPF-008

DRUG3 trials

Sponsors

Xenon Pharmaceuticals Inc.

Conditions

Adult focal (partial onset) epilepsyHealthy Male VolunteersHealthy Volunteers

Phase 1

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

CompletedNCT03340220

Xenon Pharmaceuticals Inc.Healthy Volunteers

Start: 2017-11-13End: 2021-11-26Updated: 2023-05-11

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

CompletedNCT03468725

Xenon Pharmaceuticals Inc.Healthy Male Volunteers

Start: 2018-02-13End: 2018-07-31Updated: 2018-09-18

Phase 2

A Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Epilepsy, With an Open-label Extension

Active, not recruitingCTIS2023-508681-15-00

Xenon Pharmaceuticals Inc.Adult focal (partial onset) epilepsy

Start: 2019-05-28Target: 182Updated: 2026-01-16